Several brokerages have updated their recommendations and price targets on shares of Opko Health (NASDAQ: OPK) in the last few weeks:

  • 8/12/2017 – Opko Health was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. “
  • 8/10/2017 – Opko Health had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $6.50 price target on the stock, down previously from $6.80.
  • 8/1/2017 – Opko Health was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/27/2017 – Opko Health had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $8.00 price target on the stock.
  • 7/24/2017 – Opko Health was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 7/21/2017 – Opko Health was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $7.25 price target on the stock. According to Zacks, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. “
  • 7/18/2017 – Opko Health had its price target raised by analysts at Barrington Research to $11.00. They now have an “outperform” rating on the stock.
  • 7/12/2017 – Opko Health was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. “
  • 6/22/2017 – Opko Health was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 6/16/2017 – Opko Health had its “buy” rating reaffirmed by analysts at Ladenburg Thalmann Financial Services. They now have a $19.50 price target on the stock.

Opko Health, Inc. (NASDAQ:OPK) opened at 6.145 on Tuesday. Opko Health, Inc. has a 52 week low of $5.99 and a 52 week high of $12.15. The company has a 50-day moving average of $6.36 and a 200-day moving average of $7.24. The company’s market cap is $3.44 billion.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. The firm had revenue of $314.20 million for the quarter, compared to analyst estimates of $322.64 million. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The business’s revenue for the quarter was down 12.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.02 earnings per share. On average, equities analysts expect that Opko Health, Inc. will post ($0.20) EPS for the current year.

In related news, Director John A. Paganelli acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The shares were bought at an average price of $6.17 per share, with a total value of $30,850.00. Following the completion of the transaction, the director now directly owns 350,340 shares in the company, valued at $2,161,597.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Phillip Md Et Al Frost acquired 70,800 shares of the company’s stock in a transaction that occurred on Wednesday, May 17th. The shares were bought at an average cost of $6.54 per share, for a total transaction of $463,032.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $20,070,939.54. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 1,613,200 shares of company stock worth $10,273,059. Insiders own 40.19% of the company’s stock.

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Receive News & Ratings for Opko Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.